Substrate reduction therapy in the infantile form of Tay-Sachs disease

B. Bembi; F. Marchetti; V. I. Guerci; G. Ciana; R. Addobbati; D. Grasso; R. Barone; R. Cariati; L. Fernandez-Guillen; T. Butters; M. G. Pittis

doi:10.1212/01.wnl.0000194225.78917.de

Substrate reduction therapy in the infantile form of Tay-Sachs disease

B. Bembi, F. Marchetti, V. I. Guerci, G. Ciana, R. Addobbati, D. Grasso, R. Barone, R. Cariati, L. Fernandez-Guillen, T. Butters, M. G. Pittis

IRCCS pediatrico Burlo Garofolo

Research output: Contribution to journal › Article

Abstract

Substrate reduction therapy (SRT) with miglustat has been proposed for treatment of some lysosomal storage disorders. Based on the positive experience in Gaucher disease and experimental data in Tay-Sachs (TSD) and Sandhoff animal models, the authors investigated the clinical efficacy of SRT in two patients with infantile TSD. SRT could not arrest the patients' neurologic deterioration. However, a significant drug concentration in CSF as well as macrocephaly prevention were observed.

Original language	English
Pages (from-to)	278-280
Number of pages	3
Journal	Neurology
Volume	66
Issue number	2
DOIs	https://doi.org/10.1212/01.wnl.0000194225.78917.de
Publication status	Published - Jan 2006

ASJC Scopus subject areas

Neuroscience(all)

Access to Document

10.1212/01.wnl.0000194225.78917.de

Fingerprint Dive into the research topics of 'Substrate reduction therapy in the infantile form of Tay-Sachs disease'. Together they form a unique fingerprint.

Cite this

Bembi, B., Marchetti, F., Guerci, V. I., Ciana, G., Addobbati, R., Grasso, D., Barone, R., Cariati, R., Fernandez-Guillen, L., Butters, T., & Pittis, M. G. (2006). Substrate reduction therapy in the infantile form of Tay-Sachs disease. Neurology, 66(2), 278-280. https://doi.org/10.1212/01.wnl.0000194225.78917.de

@article{56a45b5b0d014496ae09adc505acd857,

title = "Substrate reduction therapy in the infantile form of Tay-Sachs disease",

abstract = "Substrate reduction therapy (SRT) with miglustat has been proposed for treatment of some lysosomal storage disorders. Based on the positive experience in Gaucher disease and experimental data in Tay-Sachs (TSD) and Sandhoff animal models, the authors investigated the clinical efficacy of SRT in two patients with infantile TSD. SRT could not arrest the patients' neurologic deterioration. However, a significant drug concentration in CSF as well as macrocephaly prevention were observed.",

author = "B. Bembi and F. Marchetti and Guerci, {V. I.} and G. Ciana and R. Addobbati and D. Grasso and R. Barone and R. Cariati and L. Fernandez-Guillen and T. Butters and Pittis, {M. G.}",

year = "2006",

month = jan,

doi = "10.1212/01.wnl.0000194225.78917.de",

language = "English",

volume = "66",

pages = "278--280",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Substrate reduction therapy in the infantile form of Tay-Sachs disease

AU - Bembi, B.

AU - Marchetti, F.

AU - Guerci, V. I.

AU - Ciana, G.

AU - Addobbati, R.

AU - Grasso, D.

AU - Barone, R.

AU - Cariati, R.

AU - Fernandez-Guillen, L.

AU - Butters, T.

AU - Pittis, M. G.

PY - 2006/1

Y1 - 2006/1

N2 - Substrate reduction therapy (SRT) with miglustat has been proposed for treatment of some lysosomal storage disorders. Based on the positive experience in Gaucher disease and experimental data in Tay-Sachs (TSD) and Sandhoff animal models, the authors investigated the clinical efficacy of SRT in two patients with infantile TSD. SRT could not arrest the patients' neurologic deterioration. However, a significant drug concentration in CSF as well as macrocephaly prevention were observed.

AB - Substrate reduction therapy (SRT) with miglustat has been proposed for treatment of some lysosomal storage disorders. Based on the positive experience in Gaucher disease and experimental data in Tay-Sachs (TSD) and Sandhoff animal models, the authors investigated the clinical efficacy of SRT in two patients with infantile TSD. SRT could not arrest the patients' neurologic deterioration. However, a significant drug concentration in CSF as well as macrocephaly prevention were observed.

UR - http://www.scopus.com/inward/record.url?scp=33644922391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644922391&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000194225.78917.de

DO - 10.1212/01.wnl.0000194225.78917.de

M3 - Article

C2 - 16434676

AN - SCOPUS:33644922391

VL - 66

SP - 278

EP - 280

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -